Cargando…
Phase 2 Trial of Nivolumab and Ramucirumab for Relapsed Mesothelioma: HCRN-LUN15-299
INTRODUCTION: We hypothesized that ramucirumab could increase previously reported objective response rate (ORR) of 11% of single-agent nivolumab in the second-line therapy of unresectable mesothelioma. METHODS: This was a cooperative group, single-arm, phase 2 trial enrolling patients with unresecta...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689266/ https://www.ncbi.nlm.nih.gov/pubmed/38046376 http://dx.doi.org/10.1016/j.jtocrr.2023.100584 |